AstraZeneca: TROPION-Breast01 Phase III Trial Fails To Achieve Statistical Significance

(RTTNews) - AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan or Dato-DXd compared to the investigator's choice of chemotherapy did not demonstrate statistical significance in the final https://www.nasdaq.com/articles/astrazeneca-tropion-breast01-phase-iii-trial-fails-achieve-statistical-significance